Drug treatment and novel drug target against Cryptosporidium

Parasite

Volumn 15, Issue 3, 2008, Pages 275-281

  Gargala, G ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

AIDS; Cryptosporidiosis; EGR R inhibitor; Nitazoxanide; Thiazolides

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; GERBILLINAE;

EID: 51149106321     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/2008153275     Document Type: Conference Paper

References (62)

1. ABUBAKAR I., ALIYU S.H., ARUMUGAM C., USMAN N.K. & HUNTER P.R. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br. J. Clin. Pharmacol., 2007, 63 (4), 387-393.
2. AKIYAMA T., ISHIDA J., NAKAGAWA S., OGAWARA H., WATANABE S., ITOH N., SHIBUYA M. & FUKAMI Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 1987, 262 (12), 5592-5595.
3. AMADI B., MWIYA M., MUSUKU J., WATUKA A., SIANONGO S., AYOUB A. & KELLY P. Effect of NTZ on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet, 2002, 360 (9343), 1375-1380.
4. ARMITAGE K., FLANIGAN T., CAREY J., FRANK I., MACGREGOR R., ROSS P. GOODGAME R. & TURNER J. Treatment of cryptosporidios with paromomicyn. A report of five cases. Arch. Intern. Med., 1992, 152 (12), 2497-2499.
5. BACCHI C.J. & YARLETT N. Polyamine metabolism as chemotherapeutic target in protozoan parasites. Mini. Rev. Med. Chem., 2002, 2 (6), 553-563.
6. BAISHANBO A., GARGALA G., DUCLOS C., FRANÇOIS A., ROSSIGNOL J.F., BALLET J.J. & FAVENNEC L. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob. Chemother., 2006, 57 (2), 353-355.
7. BISSUEL F., COTTE L., RABODONIRINA M., ROUGIER P., PIENS M.A. & TREPO C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin. Infect. Dis., 1994, 18 (3), 447-449.
8. BLAGBURN B.L., DRAIN K.L., LAND T.M., KINARD R.G., MOORE P.H., LINDSAY D.S., PATRICK D.A., BOYKIN D.W. & TIDWELL R. R. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide and paromomycin against C. parvum infections in a neonatal mouse model. Antimicrob. Agents Chemother., 1998, 42 (11), 2877-2882.
9. BLIKSLAGER A., HUNT E., GUERRANT R., RHOADS M. & ARGENZIO R. Glutamine transporter in crypts compensates for loss of villus absorption in bovine cryptosporidiosis. Am. J. Physiol. Gastrointest. Liver. Physiol., 2001, 281 (3), G645-G653.
10. BOROWITZ S.M. & SAULSBURY F.T. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J. Pediatr., 1991, 119 (4), 593-595.
11. CACCIO S., PINTER E., FANTINI R., MEZZAROMA I. & POZIO E. Human infection with Cryptosporidium felis: Case report and literature review. Emerg. Infect. Dis., 2002, 8 (1), 85-86.
12. CAI X., WOODS K.M., UPTON S.J. & ZHU G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob. Agents Chemother., 2005, 49 (11), 4437-4442.
13. CIEZY K., GOLD J., BLAZE J. & JONES P. Paromomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS, 1991, 5 (9), 1146-1147.
14. COLFORD J.M. JR., TAGER I.B., HIROZAWA A.M., LEMP G.F., ARAGON T. & PETERSEN C. Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival. Am. J. Epidemiol., 1996, 144 (9), 807-816.
15. CRABB J.H. Antibody-based immunotherapy of cryptosporidiosis. Adv. Parasitol., 1998, 40, 121-149.
16. DE LA TRIBONNIERE X., VALETTE M. & ALFANDARI S. Oral nitazoxanide and paromomycin inhalation for systemic cryptosporidiosis in a patient with AIDS. Infection, 1999, 27 (3), 232.
17. DIONISIO D., ORSI A., STERRANTINO G., MELI M., DI LOLLO S., IBBA MANNESCHI L., TROTTA M., POZZI M., SANI L. & LEONCINI F. Chronic cryptosoporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J. Clin. Pathol., 1998, 51 (2), 138-142.
18. ESPOSITO M., MOORES S., NAGULESWARAN A., MÜLLER J. & HEMPHILL A. Induction of tachyzoite egress from cells infected with the protozoan Neospora caninum by nitro- and bromo-thiazolides, a class of broad-spectrum anti-parasitic drugs. Int. J. Parasitol., 2007a, 37 (10), 1143-1152.
19. ESPOSITO M., MÜLLER N. & HEMPHILL A. Structure-activity relationships from in vitro efficacies of the thiazolide series against the intracellular apicomplexan protozoan Neospora caninum. Int. J. Parasitol., 2007b, 37 (2), 183-190.
20. ESPOSITO M., STETTLER R., MOORES S.L., PIDATHALA C., MÜLLER N., STACHULSKI A., BERRY N.G., ROSSIGNOL JF. & HEMPHILL A. In vitro efficacies of nitazoxanide and other thiazolides against Neospora caninum tachyzoites reveal antiparasitic activity independent of the nitro group. Antimicrob. Agents Chemother., 2005, 49 (9), 3715-3723.
21. + lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant? Pediatr. Transplant., 2007, 11 (1), 113-116.
22. FICHTENBAUM C.J., RITCHIE D.J. & POWDERLY W.G. Use of paromomycin for treatment of Cryptosporidium in patients with AIDS. Clin. Infect. Dis., 1993, 16 (2), 298-300.
23. nd edn. Long S.S., Pickering L.K., Prober C.G (eds), Philadelphia: Churchill Livingstone, 2003, 1267-1269.
24. GARGALA G., DELAUNAY A., FAVENNEC L., BRASSEUR P. & BALLET J.J. Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. Int. J. Parasitol., 1999, 29 (5), 703-709.
25. GARGALA G., DELAUNAY A., LI X., BRASSEUR PH., FAVENNEC L. & BALLET J.J. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J. Antimicrob. Chemother., 2000, 46 (1), 57-60.
26. GARGALA G., BAISHANBO A., FAVENNEC L., FRANÇOIS A., BALLET J.J. & ROSSIGNOL J.F. Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum and C. parvum development. Antimicrob. Agents Chemother., 2005, 49 (11), 4628-4634.
27. GREENBERG P.D. & CELLO J.P. Treatment of severe diarrhea caused by C. parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1996, 13 (4), 348-354.
28. GRIFFITHS J.K., BALAKRISHNAN R., WIDMER G. & TZIPORI S. Paromomycin and genecitin inhibit intracellular C. parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect. Immun., 1998, 66 (8), 3874-3883.
29. Guerrant R.L. Cryptosporidiosis: An emerging, highly infectious threat. Emerg. Infect. Dis., 1997, 3 (1), 51-57.
30. GUITARD J., MENOTTI J., DESVFAUX A., ALIMARDANI P., PORCHER R., DEROUIN F. & KAPEL N. Experimental study of the effects of probiotics on C. parvum infection in neonatal rats. Parasitol. Res., 2006, 99 (5), 522-527.
31. HEMPHILL A., MUELLER J. & ESPOSITO M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for die treatment of gastrointestinal infections. Expert. Opin. Pharmacother., 2006, 7 (7), 953-964.
32. HEWITT R.G., YIANNOUTSOS C.T., HIGGS E.S. CAREY J.T., GEISELER P.J., SOAVE R., ROSENBERG R., VAZQUEZ G.J., WHEAT L.J., FASS R.J., ANTONINIEVIC Z., WALAWANDER A.L., FLANIGAN T.P. & BENDER J.F. Paromomycin: no more effective than placebo for treatment of Cryptosporidiosis in patients with advanced human immunodeficiency virus infection. Clin. Infect. Dis., 2000 , 31 (4), 1084-1092.
33. HOMMER V., EICHHOLZ J. & PETRY F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of C. parvum. J. Antimicrob. Chemother., 2003, 52 (3), 359-364.
34. KADAPPU K.K., NAGARAJA M.V., RAO P.V. & SHASTRY B.A. Azithromycin as treatment for ceyprosporidiosis in human immunodeficiency virus disease. J. Postgrad. Med., 2002, 48 (3), 179-181.
35. KUHLS T.L., ORLICEK S.L., MOSIER D.A., CRAWFORD D.L., ABRAMS V.L. & GREENFIELD R.A. Enteral human serum immunoglobulin treatment of Cryptosporidiosis in mice with severe combined immunodeficiency. Infect. Immun., 1995, 63 (9), 3582-3586.
36. LEMETEIL D., ROUSSEL F., FAVENNEC L., BALLET, J.J. & BRASSEUR P. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. J. Infect. Dis., 1993, 167 (3), 766-768.
37. LI X., BRASSEUR P., AGNAMEY P., LEMEIHL D., FAVENNEC L., BALLET J.J. & ROSSIGNOL J.F. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol. (Praha), 2003, 50 (1), 19-22.
38. MAC KENZIE W.R., HOXIE N.J., PROCTOR M.E., GRADUS M.S., BLAIR K.A., PETERSON D.E., KAZMIERCZAK J.J., ADDISS D.G., Fox K.R., ROSE J.B. & DAVIS J.P. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N. Engl. J. Med., 1994, 331 (3), 161-167.
39. MELE R., GOMEZ MORALES M.A., TOSINI F. & POZIO E. Indinavir reduces C. parvum infection in both in vitro and in vivo models. Int. J. Parasitol., 2003, 33 (7), 757-764.
40. MIAO Y.M., AWAD-EL-KARIEM P.M., FRANZEN C., ELLIS D.S., MÜLLER A., COUNIHAN H.M., HAYES P.J. & GAZZARD B.G. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr., 2000, 25 (2), 124-129.
41. 31P NMR of Apicomplexans and the effects of risedronate on C. parvum Growth Biochem. Biophys. Res. Commun., 2001, 284 (3), 632-637.
42. MÜLLER J., NAGULESWARAN A., MÜLLER N. & HEMPHILL A. Neospora caninum: Functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol., 2007, in press.
43. NAGULESWARAN A., ALAEDDINE F., GUIONAUD C., VONLAUFEN N., SONDA S., JENOE P., MEVISSEN M. & HEMPHILL A. Neospora caninum protein disulfide isomerase is involved in tachyzoite-host cell interaction. Int. J. Parasitol., 2005, 35 (13), 1459-1472.
44. NORD J., MA P., DIJOHN D., TZIPORI S. & TACKET C.O. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. AIDS, 1990, 4 (6), 581-584.
45. PAPE J.W., LEVINE E., BEAULIEU M.E., MARSHALL F., VERDIER R. & JOHNSON W.D. Jr. Cryptosporidiosis in Haitian children. Am. J. Trop. Med. Hyg., 1987, 36 (2), 333-337.
46. REHG J.E. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. J. Infect. Dis., 1994, 170 (4), 934-938.
47. RIGGS M.W., SCHAEFER D.A., KAPIL S.J., BARLEY-MALONEY L. & PERRYMAN L.E. Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis. Antimicrob. Agents Chemother., 2002, 46 (2), 275-282.
48. ROSSIGNOL J.F., HIDALGO H., FEREGRINO M., HIGUERA F., GOMEZ W.H., ROMERO J.L., PADIERNA J., GEYNE A. & AYERS M.S. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients. Trans. R. Soc. Trop. Med. Hyg., 1998, 92 (6), 663-666.
49. ROSSIGNOL J.F., AYOUB A. & AYERS M.S. Treatment of diarrhea caused by C. parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis., 2001, 184 (1), 103-106.
50. ROSSIGNOL J.F. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment. Pharmacol. Ther., 2006, 24 (5), 887-894
51. ROSSIGNOL J.F., KABIL S.M., YOUNIS A.M. & EL-GOHARY Y. Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immuno-competent adults and adolescents from the Nile delta of Egypt. Clin. Gastroenterol. Hepatol., 2006, 4 (3), 320-324
52. SMITH N.H., CRON S., VALDEZ L.M., CHAPPELL C.L. & WHITE A.C. Jr. Combination drug therapy for cryptosporidiosis in AIDS. J. Infect. Dis., 1998, 178 (3), 900-903
53. STACHULSKI A.V., BERRY N.G., LILIAN LOW A.C., MOORES S.L., ROW E., WARHURST D.C., ADAGU L.S. & ROSSIGNOL J.F. Identification of isoflavone derivatives as effective anticryptosporidial agents in vitro and in vivo. J. Med. Chem., 2006, 49 (4), 1450-1454.
54. THEODOS C.M., GRIFFITHS J.K., D'ONFRO J., FAIRFIELD A. & TZIPORI S. The efficacy of nitazoxanide against C. parvum in cell culture and in animal models. Antimicrob. Agents Chemother., 1998, 42 (8), 1959-1965.
55. TZIPORI S. & WIDMER G. The biology of Cryptosporidium. Contrib. Microbiol., 2000, 6, 1-32.
56. UIP D.E., LIMA A.L.L., AMATO V.S., BOULOS M., NETO V.A. & BEM DAVID D. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients AIDS. J. Antimicrob. Chemotber., 1998, 41 (Suppl. B), 93-97.
57. VEDADI M., LEW J., ARTZ J., AMANI M., ZHAO Y., DONG A., WASNEY G.A., GAO M., HILLS T., BROKX S., QIU W., SHARMA S., DIASSITI A., ALAM Z., MELONE M., MULICHAK A., WERNIMONT A., BRAY J., LOPPNAU P., PLOTNIKOVA O., NEWBERRY K., SUNDARARAJAN E., HOUSTON S., WALKER J., TEMPEL W., BOCHKAREV A., KOZIERADZKI I., EDWARDS A., ARROWSMITH C., ROOS D., KAIN K. & HUI R. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol., 2007, 151 (1), 100-110.
58. WALLACE M.R., NGUYEN M.T. & NEWTON J.A.J. Use of paromomycin for the treatment of cryptosporidiosis in patients with AIDS. Clin. Infect. Dis., 1993, 17 (6), 1070-1073.
59. WHITE A.C. JR, CHAPPELL C.L., HAYAT C.S., KIMBALL K.T., FLANIGAN T.P. & GOODGAME R.W. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis., 1994, 170 (2), 419-424.
60. YARLETT N., WU G., WATERS W.R., HARP J.A., WANNEMUEHLER M.J., MORADA M., ATHANASOPOULOS D., MARTINEZ M.P., UPTON S.J., MARTON L.J. & FRYDMAN B.J. C. parvum spermidine/spermine N1-acetyltransferase exhibits different characteristics from the host enzyme. Mol. Biochem. Parasitol., 2007, 152 (2), 170-180.
61. YARLETT N., WATERS W.R., HARP J.A., WANNEMUEHLER M.J., MORADA M., BELLCASTRO J., UPTON S.J., MARTON L.J. & FRYDMAN B.J. Activities of DL-alpha-difluoromethylarginine and polyamine analogues against C. parvum infection in a T-cell receptor alpha-deficient mouse model. Antimicrob. Agents Chemother., 2007, 51 (4), 1234-1239.
62. ZARDI E.M., PICARDI A. & AFELTRA A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy, 2005, 51 (4), 193-196.